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The number of individuals with Alzheimer’s disease
(AD) continues to grow worldwide with the aging of the
population [1]. Although a handful of modestly effective
symptomatic treatments have been developed using the
typical randomized clinical trial (RCT) design, clinical trials
to identify effective disease-modifying treatments have been
uniformly negative [2]. There are several potential causes of
these negative trials, including the lack of efficacy in the
treatments, insensitivity of the primary outcome to treatment
changes, and low power due to the inaccurate pretrial esti-
mates of the treatment effect. Therefore, clinical trial de-
signs allowing interim analyses and the resultant
modification of the ongoing trial to increase power haveuthor. Tel.: 11-205-826-8967; Fax: 11-205-975-
oqiao@uab.edu
16/j.trci.2015.03.002
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).been recommended [3]. One such approach is the sample
size re-estimation (SSR) adaptive design, which allows sam-
ple size adjustment based on the comparison between the
interim treatment effect (or the interim variance) to the pre-
trial treatment effect (or the pretrial variance) [4].
The typical RCT design starts with a prespecified sample
size, and modifications would not be allowed after the trial
has started. In the absence of dropouts, the trial would end
with the same sample size as specified at the beginning.
The SSR adaptive design allows the sample size to increase
when the pretrial treatment effect size was overestimated or
the pretrial variance of the outcome was underestimated,
leading to a trial that concludes using a larger sample size
to retain the power specified at the beginning. It can allow
early stopping or an overall decrease in the sample size
when the pretrial treatment effect size was underestimated
or the pretrial variance was overestimated, leading to a trial
with the prespecified power but a smaller sample size,imer’s Association. This is an open access article under the CC BY-NC-ND
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cacy, but also provides other advantages over the RCT design,
such as minimizing the number of patients exposed to inferior
treatments, avoiding long-term trials for drugs with limited
efficacy, and better using the most recent external or internal
information of the ongoing trial. Potential concerns about us-
ing SSR include the reliability in estimating the overall treat-
ment effect based on relatively small interim samples (or, for
longitudinal trials, the precision in predicting the final treat-
ment effect using only the early measurements), and the
trade-off between the gain in power versus the burden to re-
cruit more subjects. The former concern is particularly rele-
vant for AD trials, as heterogeneity in the course of the
disease may introduce significant inaccuracies in estimating
the final treatment effect based on interim analyses. This
study used simulations based on real patient data to investi-
gate the SSR adaptive designs for AD trials.2. Methods
2.1. Study overview
Of the 19 studies in our meta-database [5], we excluded
seven studies that did not collect Alzheimer’s Disease
Assessment Scale-cognitive subscale (ADAS-Cog) data,
four trials with duration less than 18 months, one trial
enrolling only normal subjects, and one trial enrolling only
moderate AD, yielding six studies that were used for the
simulation (Supplementary Table 1). The primary outcome
was the ADAS-Cog, which evaluates memory, reasoning,
orientation, praxis, language, and word finding difficulty,
and is scored from 0 to 70 errors, with higher scores indi-
cating greater impairment [6]. Clinical assessments were ob-
tained at 6-month intervals over the first 2 years.
2.2. Simulation methods
Simulations were conducted under a detailed protocol
[7], similar to our previously published approach [5,8], to
reflect clinical trials for an experimental drug for AD or
MCI with one treatment group and one placebo group, 1:1
allocation ratio, and parameters for the distribution of
ADAS-Cog were selected to be consistent with previously
published trials and Alzheimer’s Disease Neuroimaging
Initiative (ADNI) ADNI [9,10].
Clinical trials with sample sizes of 50, 100, 200, 300, and
400 per group, trial durations of 12 months or 18 months for
AD and of 18 months or 24 months for MCI, and dropout
rates of 20% or 40% in both groups, were simulated. For
each scenario, subjects were randomly selected from the
meta-database with replacement, i.e., subjects from the
data set could be present more than once in the same or
different treatment groups. The placebo group outcome
was the score for the subject at the specified time point in
the meta-database, with normally distributed random error
with mean 0 and standard deviation 1 added to minimize
ties in the outcome. For each subject in the treatment group,effect sizes of 0.15 and 0.25 (representing treatment effects
of small to medium size) were used to compute simulated
treatment results. The individual treatment effect was
randomly generated from a c2 distribution with a mean equal
to the expected treatment effect (effect size times the pooled
group standard deviation) to allow for a more realistic distri-
bution of declines over time, where a few patients may fail or
worsen more markedly than would be predicted by a normal
distribution. This method introduced some extreme mea-
surements but not to the extent of violating the homoscedas-
ticity assumption of the analysis models. As successful
treatments would lead to smaller increases on the ADAS-
Cog than placebo, the individual treatment effect was shifted
by subtracting two times the expected treatment effect, then
adding the resultant to the patient’s score at the specified
time point in the database. For example, if a is the ADAS-
Cog score at a given time point, then a1 c2z22  z; is the
corresponding score in the simulated treatment group, where
z5effect size  SD and SD is the sample standard deviation
of the change in ADAS-Cog from baseline. In this example,
if a5 24, effect size is 0.25, SD is 8, and the randomly gener-
ated treatment effect from the c2z is 3, then the ADAS-Cog
score in the simulation would be 23. With this added treat-
ment effect, the mean difference in ADAS-Cog between
treatment arms and its standard deviation increased over
time (Supplementary Table 2).2.3. Time points used for SSR
Patients’ enrolment times vary in a typical trial, leading to
different numbers of availablemeasurements for each patient
at the interim analysis. In this study, for trials with given
initial sample sizes, “SSR at 12 months” means that all the
patients had enrolled and had beenmeasured for up to at least
12 months. We truncated the follow-up at the specified time
point so our results would not depend on the recruitment rate.2.4. Estimation methods used for SSR
SSR based on interim variances (henceforth, referred as
“variance only method”) and SSR based on interim effect
sizes (henceforth, referred as “effect size method”) were
used, and both methods assumed equal variances for both
treatment arms. The “variance only method” assumes that
the pretrial estimate of the mean difference between treat-
ment arms is accurate, and only the variance is uncertain
and needs re-estimation. At the interim analysis, the variance
of ADAS-Cog was estimated and compared with the pretrial
estimate, and then the sample size was adjusted based on the
following equation [11]:
N5
bs2i
bs20
N0;
whereN is the re-estimated sample size,N0 is the initial sam-
ple size, and bs2i and bs
2
0 are the interim and the estimated
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mated using pooled data (to mimic blinding to treatment in a
clinical trial) as bs2i5ðNi21Þ=ðNi22ÞðS22D2=4Þ, where Ni
is the total sample size at the interim analysis, S2 is the
pooled sample variance, and D is the pretrial estimate of
the treatment effect [12]. This method does not inflate type
I error, thus no adjustment to the a level is required.
The “effect size method” assumed that the pretrial esti-
mates of the mean difference between treatment arms and
its variance are uncertain. At the interim analysis, both
were re-estimated and the initial sample size was adjusted
based on the formula given by Chang [11]:
N5

E0
Ei

a
N0;
where E0 and Ei are the pretrial and the interim observed ef-
fect sizes, and a is a tuning parameter that is often chosen to
be 2 because of the squared relation between the sample size
and the effect size. Ei was approximated as Ei5 Di=S,
where, Di is the observed treatment difference at the interim
analysis, and S is the pooled sample deviation. This method
requires unblinding of the treatment code, which must be
monitored carefully and kept to a minimum of individuals
to preserve trial integrity. In addition, this does not preserve
the type I error, so adjustment to the a level is required. In
this study, the conservative Bonferroni correction method
was used to adjust a level [13]. If a less conservative correc-
tion method had been chosen, the gain in power after SSR
more likely would have been greater, but the relative com-
parisons would have been similar.
The pretrial variances of ADAS-Cog scores for MCI and
AD trials used in this study were 16 and 64, respectively,
which were conservatively estimated based on the placebo
outcomes of previous trials [14]. A single SSR was conduct-
ed at 6 months or 12 months. Increases in sample size are not
necessary if significance of the treatment difference is
achieved at the interim analysis, or if the treatment effect
is as large as or larger than that hypothesized a priori, or if
the variance is as small as or smaller than that hypothesized.
For both methods, we assumed restricted designs [15],
which means the initial sample size may be increased but
not decreased. The latter restriction was a practical consider-
ation, because in many chronic conditions where it takes
some time to observe change recruitment is often completed
by the time of SSR.
2.5. Statistical analysis
The primary analysis method was the Wilcoxon test of
differences in ADAS-Cog from baseline to the end of study
between the treatment group and the placebo group; missing
values were imputed using last observation carry forward
because of its simplicity and the assumption of nondifferen-
tial dropout, and the longitudinal nature of the data [16]. The
test was conducted at the end of the planned treatment period
without adjustment for covariates. The secondary analysismethod was the linear mixed effects model, which tested
the difference in the slopes of the ADAS-Cog between treat-
ment arms with adjustment for age and education [2]. For all
analyses, the missing data pattern present in the meta-
database was used to realistically simulate dropouts. Obser-
vations were missing in simulated data sets in cases where
they were originally missing in the meta-database. Because
of our use of treatment effect applied to selected samples,
differential dropout caused by informative censoring was
not included into the comparison.
One thousand simulations were carried out for each sce-
nario so that estimates of power could be obtained up to three
digits. Power is defined as the proportion of 1000 simulated
trials per scenario with P values less than or equal to .05. All
analyses were performed using SAS software, Version 9.2
(SAS Institute, 2008).3. Results
SSR at 6 months resulted in highly variable outcomes for
both sample size increases and power improvement regard-
less of SSR method (Figs. 1 and 2). Approximately 25% of
trials required at least a doubling of the sample size
regardless of initial sample sizes. When the initial sample
size was 50 per group, half of SSR projected no increase
in sample sizes. After SSR, the gain in power varied by
initial sample sizes, trial durations, and effect sizes.
For example, given an MCI trial with effect size 0.25,
duration of 18 months, and SSR at 6 months based on vari-
ances, the power on average increased from 38.8% to 61.3%
for initial sample sizes of 50 per group and from 64.7% to
88.1% for initial sample sizes of 100 per group. In contrast,
the gain in power is less dramatic for an AD trial under the
same setting, e.g., the power on average increased only
from 30.8% to 42.2% for initial sample sizes of 50 per group
and from 53.0% to 69.4% for initial sample sizes of 100 per
group. When the initial sample size was more than 200, the
gain in power was smaller regardless of the type of trials.
When the effect size was smaller, the power before and after
SSR also became smaller; but the gain in power actually
increased over larger initial sample sizes (Fig. 1). Under
the same SSR method, the longer trial duration did not
generate larger gains in power (Fig. 3). In contrast, SSR at
12 months showed greater gains in power, but were still
highly variable, ranging from 0% to 44%, with no clear in-
crease in power over larger initial sample sizes (Fig. 3).
The “effect size method” generally resulted in greater
gain in power than the “variance only method” (Fig. 2).
However, the greater gain was at the price of larger increase
in the re-estimated sample sizes (Table 1), and it diminished
over larger initial sample sizes. The two SSRmethods gener-
ated very similar results for both AD and MCI clinical trials.
On average, both the gain in power and the increase in sam-
ple sizes after SSR forWilcoxon tests are similar to those for
linear mixed effects model tests. Simulation results with
treatment effects generated from normal distributions were
Fig. 1. Power comparison before and after sample size re-estimation (SSR) based on variances at 6 months. SSR results in gain in power for small to medium
effect sizes from both Alzheimer’s disease (AD) and mild cognitive impairment (MCI) trials.
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ences were very small (data not shown).4. Discussion
Based on our simulations, in terms of power improve-
ment, SSR adaptive designs can be effective for trials with
small or medium initial sample sizes in AD and MCI. The
effectiveness depends on factors such as the number of sub-
jects accumulated for the interim analysis, the true treatment
effect size, and the type of uncertainty in the pretrial esti-
mates (effect sizes or variances). Too few subjects accumu-
lated for the interim analysis might lead to imprecise
estimates of treatment effects or variances, thus resulting
in the poor prediction of sample size adjustments; too
many subjects, subjects are already enrolled and trials
without SSR already have adequate power. The smaller the
true treatment effect, the more subjects are needed at the
interim analysis to obtain precise estimates.
It should be noted in our simulations that even after SSR,
the power for trials with small or medium initial sample sizes
is still not optimal. However, the gain in power is substantial
relative to that in the study as planned. Considering thatthese small or medium sample sizes are often used in feasi-
bility studies or phase 2 studies, missing a potentially effective
drug at that stage could be a major mistake. The application of
SSR could come to the rescue. Although the gain in power is
relatively small for trials with large initial sample sizes; SSR
can still be useful for early termination for futility. For
example, in the Vitamins B (HC) trial, at 12 months, the
mean difference in the change of ADAS-Cog from baseline
between treatment arms is 0.3 with a sample standard error
of 6.1, leading to an effect size of 0.05; compared with the hy-
pothesized effect size 0.15, it is small enough to open seri-
ously the discussions of the termination of the ongoing trial
for futility. Otherwise, the sample size has to be increased to
(.15/0.05)^2*409 5 3681 so that the initial power can be
achieved.Whether the trial would produce an undetectable ef-
fect size (i.e. the drug works with less than planned effective-
ness) or the trial would have been deemed futile if the interim
analyses had been done, it is as much a clinical decision as a
statistical one, but had an SSR process been in place, the de-
cisions could have been considered.
Although the uncertainty in the pretrial estimates deter-
mines the SSR method, the “variance only” method is
preferred over the “effect size” method [17,18], which
Fig. 2. Comparison between sample size re-estimation (SSR) at 6 months based on variances and based on effect sizes. Although both SSR methods led to gain
in power, SSR based on effect sizes led to larger gain, especially for small to medium sample sizes.
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effect. Based on our simulation, the former on average resulted
in less gain in power than the latter; however, the latter tends to
overshoot the final sample size, leading to recruitment of a
much larger number of subjects than necessary.
Finally, it has been demonstrated that group sequential de-
signs (GSDs) are more efficient than adaptive designs when
the treatment effect needs re-estimation [19,20]. However,
these studies of GSDs have assumed the variance of the
outcome is known and fixed; whereas in SSR as applied in
our study, this assumption is not required. Furthermore, the
better efficiency in GSDs is at the price of “a large number
of interim analyses, a large up-front sample size commitment
and aggressive early stopping boundaries” [21]. Thus,
although GSDs are theoretically interesting, they may not
be pragmatic in AD trials. The purpose of those GSDs is
also different from that of the SSR adaptive designs. The
former imposes a fixed maximum sample size and aims
mainly to stop the trial earlier for futility or efficacy with
well-known limitations for safety and subgroup evaluations
and potentially biased efficacy assessments. The latter allows
a flexible maximum sample size and aims primarily to
expand the study [22]. Therefore, the investigation of SSR
based on both variances and effect sizes are useful.For longitudinal studies, longer trials naturally have more
power for effective treatments. However, our simulation
indicated little difference in power between 18 months and
24 months trials after SSR. One explanation is the relatively
small treatment effect was not enough to overcome the het-
erogeneity and inconsistency inADAS-Cogwithin 6months.
This would also explain the lack of differences between SSR
at 6 months and 12 months. An alternative would be to mea-
sure more frequently and use more measurements at the
interim analysis to estimate the variances or the effect sizes.
Perhaps themost interesting result of this study is thatwhen
the sample size per arm is larger than 200, SSR generates no
major advantages over RCT designs because RCT designs
already offer adequate power. This is in contrast to the results
of many completed clinical trials with equally large or even
larger sample sizes [14,23]. The reason may be that, in our
simulations, moderate treatment effects were assumed to
exist at each measurement and persist from the beginning to
the end of the study; although in the completed trials, the
observed treatment effects were smaller and inconsistent
over time. This contrast might indicate that if a moderate,
clinically meaningful treatment effect indeed persists and
can be reflected in the change of ADAS-Cog, a large sample
would not be needed to detect it. However, in practice, the
Fig. 3. Power comparison by trial duration and by the time of sample size re-estimation (SSR) based on variances. SSR at later time points (12 months) showed
only slightly larger gain in power compared with SSR at earlier time points (6 months). There was also little gain in power with longer trials (24 months)
compared with shorter trials (18 months).
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efficient trials with moderately large sample sizes.
Although our analysis demonstrates the effectiveness of
SSR for relatively small initial sample sizes, there are
some limitations that must be considered. First, the gain in
power after SSR depends on the initial sample sizes.
Although we recommended SSR for trials with initial sam-
ple sizes less than 200 per arm, the optimal pretrial sample
size was not determined.
Second, the possible impact of the recruitment rate on the
time of SSR was not investigated. Very fast recruitment ratesTable 1
Increase in sample sizes after sample size re-estimation (SSR) by initial
sample sizes
SSR method
Initial sample sizes
50 100 200 300 400
Increase in sample sizes after SSR, mean (SD)
SSR based on
variances
43 (18) 85 (25) 170 (35) 253 (43) 338 (50)
SSR based on
effect sizes
166 (219) 210 (226) 272 (244) 303 (253) 341 (259)mean that at the interim analysis, most or even all the sub-
jects have been enrolled, and it might not be necessary to
conduct SSR given a relatively larger initial sample size,
e.g., larger than 200 per arm. However, considering failures
in completed clinical trials in AD with large sample sizes,
SSR can still be used to determine whether to stop larger tri-
als early for futility, or whether to increase the number of
longitudinal measurements instead of the number of recruits
[24]. However, we recognize that stopping a trial involves
much more than a statistical calculation.
Third, unique features of longitudinal trials might be
incorporated in SSR in the future. For example, when the
recruitment period is shorter than the trial duration, the
interim analysis may not contain any complete data. Addi-
tionally, as the variances of outcome increase over time,
the estimate of the variance at interim analyses may under-
estimate that of later time points.
Fourth, the flexibility to recruit additional subjects and
the gain in power after SSR introduces complexity of logis-
tics, masking treatment assignments, and statistical anal-
ysis.
Finally, we have not conducted a comprehensive evalua-
tion of the predictability of SSR based on earlier outcomes at
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brief investigation of the trials used for this study showed
that the predictability is acceptable. For example, in trial
HC, the effect size estimated at 12 months was 0.05, which
was much less than the hypothesized effect size 0.15; and
indeed at the end of the study, the effect size was 20.05,
which was also less than the hypothesized 0.15. Similar re-
sults were concluded from the other trials as well. With
negative trials this is certainly reasonable, but for trials
with different therapeutic mechanisms of action and thera-
peutic lags, the predictability of successful outcomes from
early measurements is harder to assess.5. Conclusion
The SSR adaptive designs can improve efficiencies for
AD and MCI trials. It can lead to significant gains in power
for trials with small or medium initial sample sizes, or avoid
the exposure of a large number of patients to ineffective treat-
ments by stopping the trial earlier for futility. Considering the
need to identify effective treatments, the continuous increase
in sample size for AD trials, and the difficulty in estimating
pretrial treatment effects, an SSR adaptive design can be a su-
perior alternative to the typical RCT design.
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RESEARCH IN CONTEXT
1. Systematic review: We reviewed existing literature
on clinical trial designs in Alzheimer’s disease
(AD). Several researchers have recommended that
novel designs such as adaptive designs should be
used to facilitate the development of effective treat-
ments instead of the double-blind, placebo
controlled, parallel group design. To provide guid-
ance, we evaluated the effect of sample size re-
estimation (SSR) in an adaptive trial designs for
AD using simulation based on a meta-database of six
AD clinical trials and observational studies.
2. Interpretation: Our results showed that SSR can be
effective for AD clinical trials with small or medium
initial sample sizes.
3. Future directions: Investigators should consider SSR
adaptive designs under appropriate circumstances.
Further research should evaluate the applicability
of novel designs for specific populations.
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Supplementary Table 1
Placebo-controlled and observational studies included in this study
Study (code) Design N Duration (months)
Selegiline, vitamin E (SL) RCT, moderate to severe AD 341 24
Memory impairment study (MIS), donepezil,
vitamin E
RCT, MCI 769 36
Simvastatin (LL) RCT, mild to moderate AD 406 18
Vitamins B (HC) RCT, mild to moderate AD 409 18
Docosahexaenoic acid (DHA) RCT, mild to moderate AD 402 18
Alzheimer’s Disease Neuroimaging Initiative
(ADNI)
Observational, AD, MCI, normal 800 36 (AD)
48 (MCI)
48 (NL)
Abbreviations: RCT, randomized clinical trial; AD, Alzheimer’s disease; MCI, mild cognitive impairment; NL, normal.
Supplementary Table 2
The mean difference (SD) in ADAS-Cog score between the placebo group and the treatment group in simulated trials
Study (code) 6 months 12 months 18 months 24 months
Selegiline, vitamin E (SL) 1.25 (1.29) 1.66 (1.64) 1.86 (1.84) 1.89 (2.21)
Memory impairment study (MIS) donepezil,
vitamin E
1.02 (0.62) 1.10 (0.69) 1.25 (0.84) 1.39 (0.95)
Simvastatin (LL) 1.45 (1.22) 1.72 (1.37) 2.13 (1.53) X
Vitamins B (HC) 1.33 (0.99) 1.54 (1.12) 2.01 (1.40) X
Docosahexaenoic acid (DHA) 1.25 (1.11) 1.60 (1.40) 2.06 (1.65) X
ADNI MCI (ADNI) 1.10 (0.60) 1.19 (0.69) 1.33 (0.88) 1.47 (1.00)
ADNI AD (ADNI) 1.25 (0.83) 1.53 (1.10) X 2.24 (1.52)
NOTE. X means that there are no scheduled measurements at that time point.
NOTE. Sample size per group: 200, effect size: 0.25, number of simulated trials per scenario: 1000.
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